Ascendis Pharma Company Description

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.

The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.

It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma A/S

Country	Denmark
Founded	2006
Industry	Biological Products, Except Diagnostic Substances
Employees	1,017
CEO	Jan Mikkelsen

Contact Details

Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark
Phone	45 70 22 22 44
Website	ascendispharma.com

Stock Details

Ticker Symbol	A71
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Jan Mikkelsen	Chief Executive Officer
Scott Smith	Chief Financial Officer
Chad Fugure	Head of Investor Relations